Bayer AG
Financial Performance
Bayer Revenue & Financials
Revenue
~$51.5B (FY2025)
Market Cap
$47.1B
Employees
88,078
What is Bayer's revenue?
Bayer had ~$51.5B in revenue for fiscal year 2025, down 2.2% from 2024. It reported a net loss of ~$4.1B.
- Latest revenue
- ~$51.5B (FY2025)
- Year-over-year
- -2.2%
- Growth rate (CAGR)
- 3.3% over 8 years
- Peak revenue
- ~$57.3B (FY2022)
- Years of data
- 9
- Employees
- 88,078
- How much profit does Bayer make?
- Bayer reported a net loss of ~$4.1B for fiscal year 2025. reports.bayer.com
- How many employees does Bayer have?
- Bayer has about 88,078 employees.
Financial Analysis
Bayer's accounts still carry the 2018 Monsanto acquisition. FY2025 sales were ~$51.5 billion (EUR 45,575 million), down 2.2 percent as reported and up 1.1 percent adjusted for currency and portfolio. EBITDA before special items was ~$11 billion (EUR 9.7 billion) and free cash flow ~$2.35 billion (EUR 2,084 million), yet the group reported an EBIT of minus ~$1.22 billion (EUR 1,077 million) and a net loss of ~$4.09 billion (EUR 3,620 million), because other operating expenses net of income reached minus ~$8.34 billion (EUR 7,377 million), mainly litigation provisions. Net financial debt fell 8.5 percent to ~$33.7 billion (EUR 29,843 million). The dividend has stayed at the legally required minimum of EUR 0.11 per share since 2023, so cash goes to debt and settlements rather than shareholders. Bayer AG is a massive German multinational pharmaceutical and biotechnology company, carrying a market valuation typically over $30 billion.
Revenue Trend Analysis
YoY Change
-2.2%
8-Year CAGR
+3.3%
Peak Year
2022
Trend
Mostly Growing
Bayer AG has 9 full fiscal year figures on this page, compounding at +3.3% annually over 8 years. The most recent year saw a 2.2% decline versus the prior year. Annual revenue peaked in fiscal year 2022 at ~$57.3B. Of 8 comparable year-over-year steps, 4 showed growth and 4 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Net Income | YoY Change | Source |
|---|---|---|---|---|
| FY2025 | ~$51.5B | -~$4.1B | -2.2% | Bayer Annual Report 2025, consolidated income statements Fiscal year ended 2025-12-31. Sales down 2.2 percent as reported, up 1.1 percent currency- and portfolio-adjusted. Net income is the amount attributable to Bayer AG stockholders. |
| FY2024 | ~$52.7B | -~$2.9B | -2.2% | Bayer Annual Report 2025, consolidated income statements Fiscal year ended 2024-12-31. Net income is the amount attributable to Bayer AG stockholders. |
| FY2023 | ~$53.8B | -~$3.3B | -6.1% | Bayer FY2023 financial news conference release; net income per the Bayer Annual Report 2023 multiyear overview Fiscal year ended 2023-12-31. Dividend cut to the legally required minimum of EUR 0.11 per share. |
| FY2022 | ~$57.3B | ~$4.7B | +15.1% | Bayer FY2022 financial news conference release; net income per the Bayer annual report multiyear overview Fiscal year ended 2022-12-31. Sales up 8.7 percent currency- and portfolio-adjusted; dividend raised 20 percent to EUR 2.40 per share. |
| FY2021 | ~$49.8B | ~$1.1B | +6.5% | Bayer FY2021 financial news conference release; net income per the Bayer annual report multiyear overview Fiscal year ended 2021-12-31. Proposed dividend EUR 2.00 per share. |
| FY2020 | ~$46.8B | -~$11.9B | -4.9% | Bayer FY2020 financial news conference release; net income per the Bayer annual report multiyear overview Fiscal year ended 2020-12-31. The net loss reflects glyphosate litigation provisions and Crop Science impairments. |
| FY2019 | ~$49.2B | ~$4.6B | +10.0% | Bayer FY2019 results release; net income per the Bayer annual report multiyear overview Fiscal year ended 2019-12-31. Sales up 3.5 percent currency- and portfolio-adjusted. |
| FY2018 | ~$44.7B | ~$1.9B | +13.1% | Bayer FY/Q4 2018 results release; net income per the Bayer annual report multiyear overview Fiscal year ended 2018-12-31, as reported, with Monsanto consolidated from June 2018. Later restated to ~$41.5 billion (EUR 36,742 million) once Animal Health was classified as a discontinued operation. |
| FY2017 | ~$39.6B | ~$8.3B | — | Bayer FY/Q4 2017 results release; net income per the Bayer annual report multiyear overview Fiscal year ended 2017-12-31. Covestro was deconsolidated during 2017 and reported as a discontinued operation, so sales are not comparable with 2016. |
Click any row to see year details.
Keep researching Bayer
Bayer Revenue and Financial FAQ
What is Bayer AG's annual consolidated revenue scale?
Bayer AG reported revenue of ~$51.5 billion (€45.6 billion) for fiscal year 2025, down from ~$52.7 billion (€46.6 billion) in fiscal 2024.
What is Bayer's EBITDA before special items and profitability profile?
Bayer posted EBITDA before special items of ~$11 billion (EUR 9.7 billion) in 2025, down 4.5 percent, on sales of ~$51.5 billion (EUR 45,575 million). Reported EBIT was minus ~$1.22 billion (EUR 1,077 million) because other operating expenses net of income reached minus ~$8.34 billion (EUR 7,377 million), mainly litigation provisions. Core earnings per share were EUR 4.91.
What is Bayer's net financial debt profile following the Monsanto acquisition?
Net financial debt was ~$33.7 billion (EUR 29,843 million) at the end of 2025, down 8.5 percent from ~$36.9 billion (EUR 32,626 million) a year earlier. Free cash flow was ~$2.35 billion (EUR 2,084 million), and Bayer is holding the dividend at the legal minimum to keep funding the reduction.
What was the financial impact of the Roundup (glyphosate) litigation settlements on Bayer?
Bayer agreed to pay about USD 10.9 billion in 2020 to settle roughly 113,000 Roundup claims. About 65,000 claims were still pending in September 2026, and Monsanto has proposed a class settlement funded by declining capped annual payments of up to USD 7.25 billion over as long as 21 years to resolve current and future non-Hodgkin lymphoma claims.
What dividend policy changes did Bayer announce in 2024 to conserve cash?
Bayer amended its dividend policy in 2024 and said it would pay only the legally required minimum for three years. That is EUR 0.11 per share for 2023, 2024 and 2025, down from EUR 2.40 for 2022. Shareholders approved the 2024 payment with 99.32 percent of votes at the April 25, 2025 annual stockholders meeting.
How much capital does Bayer invest annually in Research and Development (R&D)?
Research and development spending was ~$6.52 billion (EUR 5,769 million) in 2025, or 12.7 percent of sales, down 7.1 percent as reported because of lower special charges in Crop Science. Adjusted for special items and currency it rose 5.2 percent. Pharmaceuticals accounted for ~$3.91 billion (EUR 3,456 million) and Crop Science ~$2.27 billion (EUR 2,013 million).
What credit ratings do S&P and Moody's assign to Bayer AG?
Bayer is rated investment grade. S&P Global Ratings has it at BBB with a negative outlook on litigation risk, and Fitch also rates it BBB with a negative outlook. Bayer says it still targets an A category rating over the long term.
How did Crop Science sales move in 2025?
Crop Science sales were ~$24.4 billion (EUR 21,622 million) in 2025, down 2.9 percent as reported and up 1.1 percent currency- and portfolio-adjusted. Corn Seed and Traits drove the growth, rising 9.0 percent to ~$8.08 billion (EUR 7,149 million) as US corn acreage increased, which offset the vacatur of the dicamba label in the United States and the expiry of the Movento registration in Europe.
Is Bayer losing money?
While its core operations generate massive cash flow, Bayer has suffered staggering multi-billion-dollar net losses entirely due to massive legal settlements regarding the weedkiller Roundup.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Bayer Revenue & Financials." CorpDigest, https://corpdigest.com/company/bayer/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Bayer reported ~$51.5B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/bayer/financials" target="_blank" rel="noopener">CorpDigest — Bayer financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Bayer
Core profile pages, founders and related research hubs for this company.